S7 Ep23: FDA Approval Insights: Darolutamide Plus Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer
Aug 15, 2022
13:47
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
Dr Berchuck discusses the effects of treatment intensification with darolutamide in men with metastatic hormone-sensitive prostate cancer, the significance of the approval of darolutamide plus docetaxel and androgen deprivation therapy, and lingering questions left unanswered by the pivotal ARASENS study.
OncLive® On Air